Medicenna Therapeutics Corp.
MDNAFDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder
MDNA11
Advanced Solid Tumor
MDNA55
Glioblastoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
methylphenidate hydrochloride | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
MDNA11 | Phase 2 | Advanced Solid Tumor | - | - |
MDNA55 | Phase 2 | Glioblastoma | - | - |
Frequently asked questions
What is in Medicenna Therapeutics Corp.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Medicenna Therapeutics Corp.'s (MDNAF) pipeline across Phase 3, Phase 2. Its lead program is methylphenidate hydrochloride (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Medicenna Therapeutics Corp.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Medicenna Therapeutics Corp. (MDNAF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MDNAF biotech catalysts?→
Add MDNAF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Medicenna Therapeutics Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.